Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 7/20 | 0.53 |
| ▸ | ELANE | P08246 | 2/20 | 0.49 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.47 |
| ▸ | KLK1 | P06870 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.40 |
| ▸ | PLAT | P00750 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18973504 | 1.00 | BTN3A1 (0.53) | BTN3A1ELANEPRTN3KLK1TP53 | |
| SCHEMBL22105034 | 1.00 | BTN3A1 (0.53) | BTN3A1ELANEPRTN3KLK1TP53 | |
| SCHEMBL18953088 | 1.00 | BTN3A1 (0.53) | BTN3A1ELANEPRTN3KLK1TP53 | |
| SCHEMBL15593268 | 0.94 | BTN3A1 (0.49) | BTN3A1ELANEPRTN3KLK1TP53 | |
| SCHEMBL19894592 | 0.94 | BTN3A1 (0.49) | BTN3A1ELANEPRTN3KLK1TP53 | |
| SCHEMBL24148685 | 0.92 | BTN3A1 (0.51) | BTN3A1ELANEPRTN3KLK1MEN1 | |
| SCHEMBL18973549 | 0.90 | BTN3A1 (0.60) | BTN3A1ELANEPRTN3KLK1TP53 | |
| SCHEMBL24505391 | 0.90 | BTN3A1 (0.60) | BTN3A1ELANEPRTN3KLK1TP53 | |
| SCHEMBL18973572 | 0.90 | BTN3A1 (0.52) | BTN3A1ELANEPRTN3KLK1TP53 | |
| SCHEMBL18973567 | 0.88 | BTN3A1 (0.55) | BTN3A1ELANEPRTN3KLK1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112513061-B | 4' -Thio-nucleotides and-nucleoside prodrugs for treating cancer | 南方研究院 | 2025-01-24 | — | — | CN | disclosed |
| US-20240116972-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RES INST (US) | 2024-04-11 | — | — | US | disclosed |
| US-11858956-B2 | 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections | SOUTHERN RESEARCH INSTITUTE (US) | 2024-01-02 | — | — | US | disclosed |
| EP-4262812-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | Southern Research Institute (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-4209498-A1 | 4'-THIO-NUCLEOTIDE AND -NUCLEOSIDE PRODRUGS FOR THE TREATMENT OF CANCER | Southern Research Institute (US) | 2023-07-12 | — | — | EP | disclosed |
| US-20220204545-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | OREGON HEALTH AND SCIENCE UNIVERSITY | 2022-06-30 | — | — | US | disclosed |
| WO-2022133323-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | SOUTHERN RESEARCH INSTITUTE (US) | 2022-06-23 | — | — | WO | disclosed |
| US-10913756-B2 | Phosphoramidate compound and preparation method and crystal thereof | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-02-09 | — | — | US | disclosed |
| US-20210009625-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES | LAURUS LABS PRIVATE LTD (IN) | 2021-01-14 | — | — | US | disclosed |
| US-10689413-B2 | Composition enriched in single isomer of NUC-1031 and preparation method and use thereof | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-06-23 | — | — | US | disclosed |
| US-20200190125-A1 | Phosphoramidate Compound and Preparation Method and Crystal Thereof | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204545-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | MTAP, GALE, TPMT | BTN3A1 3911/4885ELANE 2992/4885PRTN3 931/4885 |
| US-10913756-B2 | Phosphoramidate compound and preparation method and crystal thereof | SF1, SF3B1, SF3A1 | BTN3A1 3650/4885ELANE 4402/4885PRTN3 992/4885 |
| US-20200190125-A1 | Phosphoramidate Compound and Preparation Method and Crystal Thereof | SF1, SF3B1, SF3A1 | BTN3A1 3650/4885ELANE 4402/4885PRTN3 992/4885 |
| US-20210009625-A1 | DIASTEREOSELECTIVE SYNTHESIS OF PHOSPHATE DERIVATIVES | TYMP, PNP, DPYD | BTN3A1 4228/4885ELANE 4731/4885PRTN3 2082/4885 |
| US-20240116972-A1 | 6-AZA-NUCLEOSIDE PRODRUGS AS ANTIVIRAL AGENTS FOR TREATING VIRUS INFECTIONS | MTAP, GALE, TPMT | BTN3A1 3911/4885ELANE 2992/4885PRTN3 931/4885 |
| US-11858956-B2 | 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections | MTAP, GALE, TPMT | BTN3A1 3911/4885ELANE 2992/4885PRTN3 931/4885 |
| US-10689413-B2 | Composition enriched in single isomer of NUC-1031 and preparation method and use thereof | NGLY1, NUCB2, KPNB1 | BTN3A1 2234/4885ELANE 1381/4885PRTN3 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.